New York, July 14, 2026 — Shares of GE HealthCare Technologies Inc. (NASDAQ: GEHC) fell 5.6% to $61.66 on Tuesday, wiping out approximately $1.7 billion in market capitalization. The decline came after HCA Healthcare Inc. (NYSE: HCA) disclosed lower surgical volumes and a roughly $400 million impact from a less favorable payer mix, raising concerns about hospital capital spending on imaging equipment.
The sell-off in GE HealthCare outpaced the broader medical device sector. The iShares U.S. Medical Devices ETF (NYSEARCA: IHI) fell 4.13%, while GE HealthCare dropped 1.46 percentage points more. In contrast, the S&P 500 rose 0.38% on the day. Among peers, Intuitive Surgical Inc. (NASDAQ: ISRG) slid 6.78% and Medtronic plc (NYSE: MDT) declined 5.11%, reflecting the market's read-through that procedure volumes may be softening across the industry.
Imaging Orders Under Scrutiny
GE HealthCare's imaging and advanced visualization solutions business generated $3.64 billion, or about 71% of first-quarter revenue. However, organic order growth slowed to just 1.1% in the first quarter, compared with 10.3% a year earlier. The company's backlog stood at $21.8 billion, with a book-to-bill ratio of 1.07. The HCA warning has sharpened focus on the company's ability to convert that backlog into revenue, especially as hospitals may delay large imaging projects in a weaker reimbursement environment.
At Tuesday's close, GE HealthCare traded at a trailing price-to-earnings ratio of 14.77, down from roughly 15.7 at the prior close. The stock ended only 5% above its 52-week low of $58.75. In contrast, Intuitive Surgical and Medtronic retained significantly higher multiples, at 46.03 and 21.28, respectively.
HCA's Mixed Preliminary Results
HCA's preliminary second-quarter data painted a mixed picture. Same-facility admissions rose 2.5% and emergency-room visits increased 3.6%, but inpatient surgeries fell 2.3% and outpatient surgeries dropped 3.4%. The hospital operator also noted that a higher proportion of uninsured patients and a less favorable service mix cut pretax income by about $400 million. HCA reduced its full-year earnings forecast to $28.70–$30.50 per share from $29.10–$31.50. CEO Sam Hazen said the company had "adjusted our guidance to reflect these factors."
Morningstar analyst Julie Utterback commented that "momentum is stalling," pointing to the broader pressure on hospital cash generation. While patient volumes remain positive, the revenue mix is weaker, which could dampen capital expenditure on imaging equipment.
GE HealthCare's Outlook and Key Dates
GE HealthCare CEO Peter Arduini said in April that the company's revenue outlook depended on "healthy customer demand globally." Despite lowering its profit forecast due to input-cost inflation, the company maintained its projection for 3% to 4% organic revenue growth and adjusted earnings of $4.80 to $5.00 per share. The company now faces the challenge of defending the demand side of that forecast.
Some analysts caution that HCA's pressure may be largely tied to its specific payer mix, and that the read-through to broader imaging investment demand may be overly harsh. GE HealthCare's backlog remains slightly larger than its $20.6 billion annual revenue base, but backlog is not a one-year sales forecast. The bearish case still needs confirmation.
GE HealthCare is scheduled to report second-quarter results before the market opens on July 29. Investors will closely watch U.S. order growth, backlog conversion rates, and any signs that hospitals are delaying large imaging projects following HCA's warning. Timing will be critical in determining whether the current sell-off is justified or an overreaction.
